EUVIMEDEUVIMED entdecken
Crossref

Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches

Maria Silva, Joao Pereira

Asian Journal of Current Research in Clinical Cancer · 2026 · 6 (1) · 18-26

DOI: 10.51847/gouduiysfo ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2026. Verfasst von Maria Silva und 1 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A notable fraction of breast cancer occurrences stems from hereditary pathogenic mutations. Germline genetic testing (GGT), especially focused on BRCA1 and BRCA2, is an indispensable component of precision oncology, enabling tailored risk classification and the formulation of individualized treatment plans. Within this report, we investigate the practicality of performing blanket testing on all freshly diagnosed breast cancer patients, without regard for age, personal or familial cancer backgrou

Zitieren

APA

Silva, M., & Pereira, J. (2026). Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches. Asian Journal of Current Research in Clinical Cancer, 6(1), 18-26. https://doi.org/10.51847/gouduiysfo

Vancouver

Silva M, Pereira J. Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches. Asian Journal of Current Research in Clinical Cancer. 2026;6(1):18-26. doi:10.51847/gouduiysfo

BibTeX
@article{Silva2026,
  author = {Silva, Maria and Pereira, Joao},
  title = {Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches},
  journal = {Asian Journal of Current Research in Clinical Cancer},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {18--26},
  doi = {10.51847/gouduiysfo}
}
Kostenlos starten →